Evidence map›Paper›PMID 37558684›Full record

ArticleBlood cancer journal2023

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

Yi Miao, Yeqin Sha, Yi Xia, Shuchao Qin, Rui Jiang, Luomengjia Dai, Hui Shen, Tonglu Qiu, Wei Wu, Jingyan Qiu and 7 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yi Miao *Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Yeqin Sha *Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.ORCID http://orcid.org/0000-0002-7726-1749
Yi Xia *Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Shuchao Qin *Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Rui JiangDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Luomengjia DaiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Hui ShenDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Tonglu QiuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Wei WuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Jingyan QiuPukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China.
Yilian YangPukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China.
Chongyang DingDepartment of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Yujie WuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Lei FanDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.ORCID http://orcid.org/0000-0002-9368-4987
Wei XuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China. xuwei0484@jsph.org.cn.ORCID http://orcid.org/0000-0003-4208-7477
Jianyong LiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China. lijianyonglm@126.com.ORCID http://orcid.org/0000-0002-9931-4055
Huayuan ZhuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China. huayuan.zhu@hotmail.com.ORCID http://orcid.org/0000-0003-3073-6345
Jiangsu Province Hospital · CNJiangsu Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAdenineAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideEast Asian PeopleHumansPiperidinesProspective StudiesRituximabTumor Suppressor Protein p53VidarabineAdenineCyclophosphamidefludarabineibrutinibPiperidinesRituximabTP53 protein, humanTumor Suppressor Protein p53Vidarabine

Identifiers

PMID37558684
PMCPMC10412547
OpenAlexW4385707030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.